Why Episodic Lactate Measurement Is No Longer Sufficient

Blood lactate is one of the most clinically informative biomarkers in critical care, yet the dominant method of measuring it—discrete venous or arterial blood draws processed in a central laboratory—creates a fundamental information gap. As documented by the Whiston Hospital ICU group in 2021, “lactate levels can change rapidly over short spaces of time, and even subtle changes can reflect a profound change in the patient’s condition.” Conventional hourly or multi-hourly sampling may miss clinically decisive inflection points in sepsis, post-cardiac surgery recovery, and haemodynamic instability.

Continuous lactate monitoring (CLM) addresses this gap by replacing episodic sampling with real-time, uninterrupted physiological measurement. The field sits at the intersection of electrochemical biosensing, minimally invasive wearable devices, and critical care informatics. Innovation is maturing across three parallel trajectories: implantable intravascular sensors, subcutaneous and transdermal microneedle arrays, and non-invasive sweat or spectroscopic platforms. Applications span intensive care, sepsis management, perioperative monitoring, and sports performance optimization.

The foundational research in this dataset dates to 2009, when subcutaneous adipose tissue (SAT) microdialysis was first evaluated in post-cardiac surgery patients as a site for lactate measurement, demonstrating a significant correlation (r²=0.71) with arterial blood. The same year, a portable electrochemiluminescent biosensor was developed for point-of-care use by Ecsens and the University of Granada. These early proofs of concept established the technical feasibility of continuous or near-continuous lactate sensing outside the central laboratory—a premise that has since attracted academic groups, medical device majors, and venture-backed startups alike.

The Four Technical Approaches Competing for Market Position

Four distinct technical sub-domains have emerged in continuous lactate monitoring, each with a different profile of invasiveness, clinical applicability, and technical maturity. The dominant approach—electrochemical amperometric detection using lactate oxidase—underpins both implantable and microneedle-based devices. The remaining three approaches (sweat sensors, optical spectroscopy, and machine learning surrogates) offer progressively lower invasiveness at the cost of signal fidelity or clinical validation depth.

1. Implantable Electrochemical Sensors

This is the most patent-dense cluster in the dataset. The dominant technical approach uses lactate oxidase covalently bonded to a polymer matrix, overcoated with a mass transport limiting membrane—such as crosslinked polyvinylpyridine homopolymer or copolymer—to control analyte diffusion and improve long-term stability. Abbott Diabetes Care’s EP, JP, and WO patents (2025) all employ this architecture, with albumin-LOx covalent bonding and polyvinylpyridine mass transport membranes designed for in vivo continuous monitoring. The University of Michigan demonstrated an anti-thrombotic intravascular catheter integrating a continuous lactate sensor with a nitric oxide-releasing surface, enabling more than 48 hours of continuous in-blood data acquisition in an open-heart piglet model, directly addressing the fouling and thrombosis limitations that have historically constrained intravascular sensors.

2. Transdermal Microneedle Biosensors

Microneedle arrays penetrate the stratum corneum to access interstitial fluid (ISF), which approximates blood lactate with a time lag. Imperial College London conducted a phase I clinical study of a solid microneedle biosensor patch worn on the forearm, quantifying ISF lactate continuously versus venous blood and microdialysis reference during 30-minute aerobic exercise in 5 healthy volunteers. The National Taipei University of Technology developed a three-electrode system with a 3×3 stainless-steel microneedle array (1 mm length), gold-plated working electrode with polyaniline modification, targeting both sports and medical sepsis monitoring. Chuangmai (Shenzhen) Biosensing Technology Co., Ltd. filed a 2020 CN patent for an implanted lactate sensing electrode contacting interstitial fluid, paired with a skin-attached data acquisition unit and wireless data receiver.

3. Sweat-Based Wearable Sensors

Non-invasive sweat sensors measure lactate secreted through eccrine glands during physical exertion or induced by osmotic stimulation. A Keio University School of Medicine study in 23 healthy subjects and 42 cardiovascular disease patients found that sweat lactate threshold (LT1) correlated with blood LT1 at r=0.92 and with ventilatory threshold at r=0.71. A follow-up prospective clinical trial (LacS-001) in 50 heart failure patients undergoing incremental exercise testing validated sweat lactate threshold as a clinical tool for anaerobic threshold determination. North Carolina State University addressed a key limitation—sweat sensors fail without active sweating—by developing a hydrogel-based osmotic sweat withdrawal mechanism enabling measurement at rest combined with paper microfluidic colorimetric lactate assay.

4. Non-Invasive Optical and Machine Learning Approaches

Queen Mary University of London applied UV/Vis, NIR (800–2600 nm), and MIR spectroscopy to 37 PBS samples with sodium lactate (0–20 mmol/L), using multivariate analysis to build prediction models as a preclinical proof-of-concept toward non-invasive sepsis monitoring. Separately, Chiba University applied regression-based supervised machine learning to morphological arterial waveform characteristics in 48 post-operative pediatric patients, demonstrating that ML can serve as a surrogate for direct lactate measurement using existing hemodynamic monitoring infrastructure—with no lactate-specific sensor required. Both approaches are at early technical readiness levels relative to implantable and microneedle platforms, but their non-invasive nature positions them as long-term disruptors, particularly for settings where any skin penetration is undesirable, as noted in standards guidance from ISO on in vitro diagnostic performance.

Patent Landscape: Who Holds the IP and Where

Abbott Diabetes Care Inc. is the most active patent filer in this dataset, with 3 active patents across EP, JP, and WO jurisdictions—all filed or published in 2025—signaling an aggressive multi-jurisdictional protection strategy for its LOx-based continuous lactate sensor platform. This positions Abbott as the dominant near-term commercialization player, leveraging its established continuous glucose monitoring (CGM) manufacturing and regulatory infrastructure.

“Abbott Diabetes Care’s patent portfolio (EP/JP/WO, 2025) represents the clearest near-term IP barrier to entry in implantable enzymatic continuous lactate sensing; any competing implantable device developer must design around the LOx–polymer–albumin–polyvinylpyridine membrane architecture or face infringement risk in major markets.”

Abbott’s WO patent explicitly combines lactate with glucose and creatinine in a single continuous monitoring system, feeding a hospital readmission prediction model—a significant architectural evolution from single-analyte sensing. Glucovation Inc. holds a 2026 WO filing for real-time analyte monitoring during exercise, representing one of the most recent filings in the dataset. Potomac Health Solutions holds two US patents (2015 and 2018) specifically claiming real-time aerobic/anaerobic ratio feedback from non-invasive lactate sensors for training optimization.

Chuangmai (Shenzhen) Biosensing Technology Co., Ltd. represents Chinese domestic innovation with a 2020 CN filing for an implantable ISF lactate monitoring system, though its legal status is listed as inactive. Infectotest GmbH holds a pending IL patent for D-lactate electrochemical sensing—a technically differentiated approach targeting bacterial infection diagnosis rather than L-lactate metabolic monitoring. On the academic side, significant activity comes from US institutions (University of Michigan, Edwards Lifesciences/UC Irvine, North Carolina State University), UK institutions (Imperial College London, Queen Mary University of London, Heriot-Watt University), and East Asian groups (National Taipei University of Technology, Keio University, Chiba University). Patent databases maintained by WIPO and the EPO confirm that PCT and European filings in biosensor wearables have grown substantially over the 2020–2025 period, providing broader context for the CLM activity observed here.

Clinical and Commercial Applications Driving Investment

The ICU and critical care setting is the dominant application domain in this dataset, with at least 20 literature records involving ICU settings. Key use cases include sepsis management, post-cardiac surgery monitoring, ECMO support, and COVID-19 severity assessment. The University of Groningen’s trial of intravascular microdialysis in 80 cardiac surgery patients (2014) and the University of Michigan’s anti-thrombotic catheter trial in open-heart surgery piglets (2020) are exemplary device studies. Abbott Diabetes Care’s WO patent (2025) targets hospital and post-discharge settings by predicting readmission risk from continuous lactate and glucose analyte streams.

Beyond the ICU, at least 8 records address sports performance and lactate threshold determination. The Potomac Health Solutions patents (US, 2015 and 2018) specifically claim real-time aerobic/anaerobic ratio feedback from non-invasive lactate sensors. Glucovation’s 2026 WO patent targets real-time lactate measurement during exercise without blood draw, directly informing zone-based training. Regulatory bodies including the FDA have established distinct pathways for sports wellness devices versus clinical diagnostics, a distinction that shapes the commercialization strategy for CLM developers targeting the consumer market.

Additional application domains documented in this dataset include:

• Perioperative and cardiac surgery: Studies from the University of Cologne on ECMO lactate clearance (2021), Okayama University Hospital on intraoperative lactate change (2015), and randomized controlled trial evidence from the Heart Institute São Paulo on lactate-guided resuscitation (2014).
• Obstetrics and neonatal care: The University of Groningen described microdialysis integrated into a fetal scalp electrode for continuous intrapartum lactate monitoring (2020), addressing what the Heriot-Watt University review (2018) identifies as a significant unmet clinical need.
• Biomanufacturing and cell therapy: A KU Leuven study (2020) demonstrates lactate measurement as a real-time proxy for cell growth in bioprocesses, enabling model predictive control of feeding strategies in human progenitor cell cultures—an emerging industrial application.
• Emergency and prehospital care: Point-of-care devices (StatStrip, iSTAT, Lactate Pro 2, Accutrend Plus) represent the installed base against which CLM devices must compete in this setting.

Five Emerging Directions Shaping the 2026 Frontier

The most recent filings and publications (2022–2026) in this dataset reveal five forward-looking innovation signals that are likely to define competitive positioning in continuous lactate monitoring over the next three to five years.

1. Multi-Analyte Continuous Monitoring Platforms

Abbott’s WO patent (2025) explicitly combines lactate with glucose and creatinine in a single continuous monitoring system, feeding a hospital readmission prediction model. This shift from single-analyte to multi-analyte panels delivered from one implanted sensor represents a significant architectural evolution—one that mirrors the trajectory of continuous glucose monitoring toward broader metabolic panels.

2. Real-Time Athletic Performance Optimization Without Blood Draw

Glucovation’s WO (2026) and Potomac Health Solutions’ US patents (2015, 2018) both target measurement “without interrupting user activity,” with lactate informing zone-based training in real time. This consumer and prosumer sports market is emerging as a parallel commercialization pathway to clinical use, with a lower regulatory burden but different addressable market and pricing dynamics.

3. Anti-Thrombotic Intravascular Catheter Sensors

The University of Michigan’s nitric oxide-releasing catheter (2020) with integrated lactate sensor demonstrated more than 48 hours of continuous in-blood lactate acquisition—directly addressing the fouling and thrombosis limitations that have historically constrained intravascular sensors and limited their clinical adoption. This approach represents a materials science solution to a fundamental biocompatibility challenge.

4. Machine Learning as a Non-Invasive Lactate Surrogate

Chiba University’s 2022 work using arterial waveform ML prediction of lactate in 48 post-operative pediatric ICU patients opens the possibility of inferring continuous lactate without any lactate-specific sensor, leveraging existing hemodynamic monitoring infrastructure. If validated at scale, this approach could deliver continuous lactate insight to every ICU patient already connected to an arterial line—without additional hardware.

5. Fetal and Neonatal Intrapartum Monitoring

The University of Groningen’s microdialysis probe integrated into a fetal scalp electrode (2020) targets a highly specific unmet need: continuous intrapartum fetal lactate measurement to reduce false-positive CTG-driven obstetric interventions. The Heriot-Watt University review (2018) identifies this as a significant unmet clinical need where continuous monitoring could replace the current inadequate fetal heart rate plus scalp blood sampling protocol. No commercial CLM product for this indication has yet emerged in the dataset.

“D-lactate is produced by bacteria during sepsis and is not measurable by conventional clinical analyzers. A continuous D-lactate sensor would offer a pathogen-specific diagnostic signal unavailable from any current device—representing a white-space IP opportunity.”

Strategic Implications for R&D and IP Teams

Abbott Diabetes Care’s patent portfolio (EP/JP/WO, 2025) represents the clearest near-term IP barrier to entry in implantable enzymatic continuous lactate sensing. Any competing implantable device developer must design around the LOx–polymer–albumin–polyvinylpyridine membrane architecture or face infringement risk in major markets. The CGM analogy is explicit and actionable: Abbott’s multi-analyte WO patent directly leverages CGM sensor architecture for lactate, and R&D teams should study the continuous glucose monitoring regulatory and manufacturing pathway (510(k) in the US, CE-IVDR in the EU) as the most likely template for CLM device approval.

Sweat sensors face a fundamental signal fidelity challenge. Multiple studies confirm sweat lactate correlates with blood and ISF lactate during active exercise, but the relationship at rest and in clinical (non-exercise) contexts remains unvalidated. Teams pursuing sweat-based CLM for ICU or sepsis applications face a significant clinical validation burden before regulatory submission. The sports performance market offers a lower-regulatory-risk entry point—Potomac Health Solutions and Glucovation have both pursued this route—but the addressable market and pricing dynamics differ substantially from the clinical ICU/sepsis market, which may offer greater long-term value.

D-lactate sensing (Infectotest GmbH, IL 2021) is an underexplored differentiation vector. Standard LOx-based sensors detect only L-lactate; D-lactate is produced by bacteria during sepsis and is not measurable by conventional clinical analyzers. A continuous D-lactate sensor would offer a pathogen-specific diagnostic signal unavailable from any current device. Research published by institutions including Nature on sepsis biomarker panels underscores the clinical value of pathogen-specific signals in early sepsis identification, further supporting the case for D-lactate as a white-space IP opportunity.

The biomanufacturing application (KU Leuven, 2020) deserves attention as an adjacent market: continuous lactate sensing as a real-time proxy for cell growth in bioprocesses enables model predictive control of feeding strategies in human progenitor cell cultures. This industrial application operates under different regulatory constraints than clinical devices and may offer an earlier, lower-risk route to commercial deployment for teams with relevant biosensor IP. Teams can explore the full patent landscape and identify freedom-to-operate gaps using PatSnap’s innovation intelligence platform, which aggregates data across 2 billion+ data points across 120+ countries.